Wheeler Patrick C
Department of Sport & Exercise Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.
School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
J Clin Orthop Trauma. 2022 Jan 28;26:101781. doi: 10.1016/j.jcot.2022.101781. eCollection 2022 Mar.
Patella tendinopathy is a common condition in a number of sports and can have a significant impact on activity and quality of life. Whilst rehabilitation leads to improvements in the majority of cases, a number of adjunct treatments are available for resistant cases with limited evidence supporting the use of one treatment over another.Hypothesis/Purpose: To compare the outcomes for patients with chronic patella tendinopathy, following either radial-Extra-Corporeal Shockwave Therapy (r-ESWT) or Autologous Blood Injection (ABI).
Prospective cohort study.
28 consecutive patients with chronic patella tendinopathy, treated with radial-ESWT (n = 14) or ABI (n = 14), with minimum three-month follow-up. Mean age 34.2 years, mean duration of symptoms 32.8 months. Patients received either three sessions of radial-Extra-Corporeal Shockwave Therapy (one session per week for 3 weeks), or two ultrasound-guided Autologous Blood Injections (2 injections performed 2-4 weeks apart). All patients received standardised after-care, including continuation of a structured home exercise programme of flexibility and progressive loading (eccentric strengthening) exercises. Main Outcome Measures were Victoria Institute of Sport - Patella questionnaire (VISA-P), plus 0-10 Visual Analogue Scale (VAS) for self-reported levels of "average pain".
There were statistically significant improvements in self-reported measures of pain/function following either procedure at 6-weeks and at 3-months, but only in the ABI group at 6-months. At 3-months: VISA-P was improved from 32.4% ± 11.7%-60.0% ± 20.7% (p < 0.01) in the ABI group, and from 34.2% ± 14.6%-48.9% ± 17.8% (p < 0.001) in the r-ESWT group.
Patients with chronic patella tendinopathy improved at 6-weeks and 3-months following either ABI or r-ESWT procedure, with significant benefits at 6-months seen only in the ABI group. Between group analysis demonstrated improved outcomes favouring ABI compared to r-ESWT at the 6-month timepoint using VISA-P, and at all time-points using VAS as outcome measures. The small sample sizes in this pragmatic study are however noted, which limit interpretation, and larger more robust studies are required to investigate this further. This pragmatic prospective cohort study demonstrates improvements following either r-ESWT or ABI procedures, with results potentially favouring ABI over r-ESWT for patients with chronic patella tendinopathy.
髌腱病在多项体育运动中较为常见,会对活动能力和生活质量产生重大影响。虽然大多数情况下康复治疗会有改善,但对于难治性病例,有多种辅助治疗方法,不过支持一种治疗方法优于另一种治疗方法的证据有限。
假设/目的:比较慢性髌腱病患者接受径向体外冲击波疗法(r-ESWT)或自体血注射(ABI)后的治疗效果。
前瞻性队列研究。
连续纳入28例慢性髌腱病患者,分别接受径向体外冲击波疗法(n = 14)或自体血注射(n = 14),随访至少3个月。平均年龄34.2岁,平均症状持续时间32.8个月。患者接受3次径向体外冲击波疗法(每周1次,共3周),或2次超声引导下的自体血注射(2次注射间隔2 - 4周)。所有患者均接受标准化的后续护理,包括继续进行结构化的家庭锻炼计划,进行灵活性和渐进性负荷(离心强化)锻炼。主要观察指标为维多利亚运动研究所 - 髌骨问卷(VISA-P),以及用于自我报告“平均疼痛”程度的0 - 10视觉模拟量表(VAS)。
两种治疗方法在6周和3个月时,自我报告的疼痛/功能测量指标均有统计学意义的改善,但仅ABI组在6个月时有改善。3个月时:ABI组VISA-P从32.4% ± 11.7%提高到60.0% ± 20.7%(p < 0.01),r-ESWT组从34.2% ± 14.6%提高到48.9% ± 17.8%(p < 0.001)。
慢性髌腱病患者在接受ABI或r-ESWT治疗后6周和3个月时有所改善,仅ABI组在6个月时有显著益处。组间分析表明,在6个月时间点使用VISA-P,以及在所有时间点使用VAS作为观察指标时,与r-ESWT相比,ABI的治疗效果更佳。然而,本实用研究的样本量较小,限制了结果的解释,需要更大规模、更有力的研究进一步探究。这项实用的前瞻性队列研究表明,r-ESWT或ABI治疗后均有改善,对于慢性髌腱病患者,结果可能更倾向于ABI优于r-ESWT。